is there anyone who has looked at the ARGX MDS trial that doesn't think that this is why JNJ dropped imet?
https://www.argenx.com/en-GB/news-inter ... mia/30208/
So the question now is which direction GERN should go.
The JNJ-ARGX deal in MDS/AML
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
- Posts: 61
- Joined: Wed Oct 03, 2018 12:48 am
Re: The JNJ-ARGX deal in MDS/AML
Argx drug targets high risk MDS whereas Imet targets intermediate-1 or low risk patient groups. However, phenomonal success of their drug in AML may be a significant threat to Geron's future attempt to widen the scope of treatment space to include AML.